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Abstract
Objectives Intra-arterial digital subtraction angiography (DSA),
magnetic resonance angiography (MRA) and computed tomo-
graphic angiography (CTA) are imaging modalities used for
diagnostic work-up of non-traumatic subarachnoid haemorrhage.
The aim of our study was to compare the cost-effectiveness of
MRA, DSA and CTA in the first year after the bleed.
Methods A decision model was used to calculate costs and
benefits (in quality-adjusted life-years [QALYs]) that accrued
to cohorts of 1,000 patients. Costs and characteristics of
diagnostic tests, therapy, patients’ quality of life and associat-
ed costs were respected. The diagnostic strategy with highest
QALYs and lowest costs was considered most cost-effective.
Results DSAwas the most effective diagnostic option, yield-
ing on average 0.6039 QALYs (95 %CI, 0.5761–0.6327) per
patient, followed by CTA 0.5983 QALYs (95 % CI, 0.5704–
0.6278) and MRA 0.5947 QALYs (95 % CI, 0.5674–
0.6237). Cost was lowest for DSA (39,808 €; 95 % CI,
37,182–42,663), followed by CTA (40,748 €; 95 % CI,
37,937–43,831) and MRA (41,814 €; 95 % CI, 38,730–
45,146). A strategy of CTA followed by DSA if CTA was
negative or coiling deemed not feasible, was as effective as
DSA alone at average costs of 39,767€ (95 % CI, 36,903–
42,402).
Conclusion A combined strategy of CTA and DSA was
found to be the most cost-effective diagnostic approach.
Main Messages
•We defined a standard model for cost-effectiveness analysis
in diagnostic imaging.
• Comparing total 1-year health costs and benefits, CTA is
superior to MRA.
• A strategy of combining CTA and DSA was found to be the
most cost-effective diagnostic approach.
Keywords Intracranial aneurysm . Cost effectiveness .
Digital subtraction angiography .Magnetic resonance
angiography . Computed tomography angiography
Introduction
Rupture of an intracranial aneurysm is a major cause of death
and disability with an overall incidence of approximately 9 per
100,000 [1]. In the group of patients who survive the initial
bleed, the risk of rebleeding without treatment is 1–2 % per
day for the first 4 weeks with a 70 % case fatality rate [2, 3].
To prevent rebleeding from ruptured aneurysms, treat-
ment is performed as soon as feasible in order to exclude
the aneurysm from the arterial circulation [2, 4, 5]. Treatment
options are either neurosurgical clipping via craniotomy or
endovascular aneurysm occlusion by detachable platinum
coils. The ISAT trial demonstrated better clinical outcome
and significant risk reduction for endovascular treatment.
Coiling is the preferred option in patients where both treat-
ments are feasible [6–9]. Total treatment costs were found to
be slightly higher for surgical clipping compared with
endovascular coiling [10–13].
Non-traumatic subarachnoid haemorrhage (SAH) is
caused in about 85 % of patients by a ruptured intracranial
aneurysm [14]. Diagnostic imaging is required to fulfil two
tasks: (1) detect the presence of intracerebral aneurysms; (2)
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determine the most suitable treatment: endovascular coiling
or surgical clipping.
DSA is the reference standard for detecting aneurysms
and for determining the feasibility of coiling. Nevertheless
this invasive and labour-intensive technique is relatively
expensive and carries discomforts and potential risks
[15–17]. Promising non-invasive and less costly diagnostic
alternatives are computed tomographic angiography (CTA)
and magnetic resonance angiography (MRA). CTA is easily
available and can be rapidly performed in an acute setting.
The main benefit of MRA is the fact that no ionising radia-
tion is used.
Although costs and characteristics of diagnostic tests and
treatment have been reported, we found no studies determining
the optimal diagnostic pathway in patients with suspected
ruptured intracranial aneurysms. Our study aimed to compare
the cost-effectiveness of MRA, CTA and DSA in these pa-
tients. Cost-effectiveness of diagnostic tests in follow-up of
coiled aneurysms has previously been evaluated by Schaafsma
et al. [18].
Materials and methods
We previously assessed test characteristics and accuracy of
MRA (1.5 T) and CTA in 75 patients with non-traumatic
SAH [19]. Patients were recruited consecutively between
2004 and 2006, and for all patients MRA, CTA and DSA
had been performed. Informed consent was given and this
study protocol was approved by the Institutional Ethical
Committee. DSA served as the standard of reference for
aneurysm presence. Feasibility of coiling depended on the
judgment of the interventionist based on DSA, or the actual
suitability during a coiling attempt. For CTA and MRA two
experienced neuroradiologists determined the presence of an
aneurysm and judged suitability for endovascular treatment
using common criteria, like dome-to-neck ratio and absence
of branches originating from the base of the aneurysm. The
observers were blinded to the results of other imaging exam-
inations. Pooled sensitivity of CTA for the detection of
aneurysms was 91.5 % (95 % CI, 85.0–95.5) and specificity
was 94.4 % (95 % CI, 79.0–99.0). Pooled sensitivity of
MRA for the detection of aneurysms was 95.4 % (95 % CI,
89.8–98.1) and specificity was 83.3 % (95 % CI, 66.5–93.0).
Pooled sensitivity of CTA in determining feasibility of
endovascular coiling was 71.9 % (95 % CI, 59.0–82.1) and
specificity was 75.4 % (95 % CI, 62.0–85.5). Pooled sensi-
tivity of MRA in determining feasibility of endovascular
coiling was 60.6 % (95 % CI, 48.2–71.7) and specificity
was 81.4 % (95 % CI, 68.7–89.9). DSA as standard of
reference was regarded to have a sensitivity and specificity
for aneurysm detection and determination of best treatment
of 100 %.
Evaluation of costs and benefits: a decision tree
A decision tree (using Excel Software) was developed to deter-
mine differences in health benefits and costs in patients with
ruptured aneurysms for various diagnostic pathways [20]. For
patients with acute non-traumatic subarachnoid haemorrhage,
the decision tree delivers different health states due to charac-
teristics of diagnostic imaging and choice of therapy. Health
states were based onwhether patients were alive and, when they
were alive, whether they were well or disabled. Figure 1 shows
the decision tree for MRA. A hypothetical cohort of patients
passes through the model based on a 1-year period. More
specifically, a cohort of patients with non-traumatic subarach-
noid haemorrhage is divided over the different pathways in the
decision tree, based on a set of probabilities that were derived
from literature. This allowed us to synthesise evidence and
thereby to evaluate health costs of diagnostic test and treatment
as well as related quality of life and associated costs determined
by diagnostic decision. A provider (or healthcare) perspective
was used, which included only direct healthcare costs.
Basic model and scenario model
In the basic model, patients underwent DSA, MRA or CTA.
Following our standard clinical practice, if no aneurysm was
detected on CTA or MRA, an additional DSA study was
performed. Patients without an intracranial aneurysm were
not treated. In patients in whom an aneurysm was detected,
feasibility of coiling of the aneurysm was determined.
Depending on the result of each test, either a coiling or
clipping procedure was performed. In patients where false-
positive feasibility of coiling was determined by CTA or
MRA, angiography during the coiling procedure would
show no feasibility and transfer to surgical clipping would
have been performed. In case of false-negative determination
of coiling, surgical clipping would have been performed,
although coiling would have been feasible.
In a scenario analysis we explored two alternative strate-
gies. CTA and MRA are less expensive and less invasive
than DSA. However, they may incorrectly characterise an
aneurysm as not suitable for coiling. We therefore analysed
whether it is cost-effective to add DSA to the CTA and MRA
strategies only if an aneurysm is deemed not suitable for
endovascular treatment. In this scenario, in each patient in
whom an aneurysm was detected which was deemed not
suitable for coiling by MRA or CTA, an additional DSA
study was considered to be performed.
Model parameters
Sensitivity and specificity of the diagnostic tests for detec-
tion of aneurysms and determination of treatment possibility
were taken as input parameters to the decision model. For the
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costs of DSA, MRA and CTA, standard prices from the
Dutch manual for cost research were used [21]. These in-
clude expenditures for personnel, equipment, materials, main-
tenance, housing, cleaning, administration and overheads.
Total 1-year costs of surgical clipping and endovascular
coiling were derived from a literature search for western
countries [10]. Health outcome after 1 year of treatment was
derived from the ISAT trial [6, 7].
Input parameters for related utilities [22] and costs [18,
21, 23], as well as health risk of DSA, are based on available
literature [17, 24]. All costs were updated to 2010 by means
of national price index figures [25] and expressed in euros
(1 €=$ 1.32). Standard discount rates of 1.5 % for effects and
4 % for costs according to Dutch guidelines were used [21].
Table 1 shows the model input parameters and their sources.
Model assumptions
We assumed that DSA, as the standard of reference, has a
sensitivity and specificity of 100 % in detecting aneurysms
and determining feasibility of coiling. Furthermore, we assumed
no significant gender- or age-related differences in outcome, as
well as no influence due to aneurysm size or location. Patients
presenting with acute SAH without presence of a ruptured
aneurysm were assumed to have no other intracranial vascular
pathology to be treated.
Data analysis
In our model, we evaluated the outcome of diagnostic pathways
based on the input parameters in Table 1. In the base case
Fig. 1 Markov decision tree basic model showing exemplary branch
for CTA. Branches for MRA and DSA not shown in detail. TP true-
positive, FN false-negative, TN true-negative, FP false-positive test
result. Example of absolute patient numbers from base case analysis
in brackets. Input parameters derived from Table 1
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Table 1 Model input parameters
Model parameter Mean SE/SD/rangea Distribution Source
Discount rates
cDR (cost discount rate) 4 % fixed [21]
oDR (outcome discount rate) 1.5 % fixed [21]
Treatment independent parameters
Probabilities, (p)
pAneurysm in case of non-traumatic SAH 0.85 fixed [14]
Costs, c (€)
Diagnostics
cDSA 725 € fixed [21]
cMRA 252 € fixed [21]
cCTA 197 € fixed [21]
Treatment
cCoiling 38,238 € 1,833 € gamma [10]
cClipping 31,739 € 2,503 € gamma [10]
Health state costs
Number of days in nursing home per year (d) 365
Costs per day in nursing home (euros/d) 241 €
cDisability 87,975 € [21]
Event costs
cDeath 2,741 € [18, 23]
Utilities (u)
uWell 0.78 0.019 beta [18, 22]
uWell after SAH 0.72 0.65–0.80 triangular [18, 22]
uDisabled 0.25 0.21–0.30 triangular [18, 22]
uDead 0.00 fixed [18, 22]
Clinical outcome probabilities
Probability of being well after clipping 0.69 0.014 beta [7]
Probability of being disabled after clipping 0.21 0.013 beta [7]
pClipdead (probability of being dead after clipping) 0.10 0.009 beta [7]
pClipwell (probability of being well after survived clipping) 0.77 [7]
Probability of being well after coiling 0.76 0.013 beta [7]
Probability of being disabled after coiling 0.16 0.011 beta [7]
pCoildead (probability of being dead after coiling) 0.08 0.008 beta [7]
pCoilwell (probability of being well after survived coiling) 0.83 [7]
Probability of being well after DSA 0.998 0.001 beta [17, 24]
Probability of being disabled after DSA 0.002 0.001 beta [17, 24]
pDSAdead (probability of being dead after DSA) 0.000 fixed [17, 24]
pDSAwell (probability of being well after survived DSA) 0.998
Probability of being dead/disabled after surgery without aneurysm
pSurgdead 0.025 0.004 beta [30]
pSurgdisab 0.132 0.008 beta [30]
pCoilTP (probability coiling is feasible in true-positive aneurysm) 0.585 0.061 beta [19]
pCoilFP (probability coiling is feasible in false-positive aneurysm) 0 fixed [19]
Treatment dependent parameters Value SE/SD/rangea Distribution Source
Probabilities
pMRAtpD (sensitivity of MRA in diagnosing aneurysm) 0.954 0.018 beta [19]
pMRAtnD (specificity of MRA in diagnosing aneurysm) 0.833 0.061 beta [19]
pCTAtpD (sensitivity of CTA in diagnosing aneurysm) 0.915 0.024 beta [19]
pCTAtnD (specificity of CTA in diagnosing aneurysm) 0.944 0.038 beta [19]
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analysis, the average costs and effects were calculated for a
hypothetical cohort of 1,000 patients.We compared total 1-year
costs of diagnostic test, treatment option and health state to 1-
year health benefits in terms of quality-adjusted life-years
(QALYs). The alternative that yielded the highest number of
QALYs was considered to be most effective. The current
analysis was performed from a decision-analytic perspective.
This implies that for an intervention to be adopted, it has to be
cost-effective compared with its next best alternative [26]. If a
strategy is less costly and more effective, it is superior to and
dominates the alternative strategy. If a strategy is more costly
and less effective than its alternative, it is dominated by the
alternative. In case the strategy is more costly and more effec-
tive, or less costly and less effective than the alternative, incre-
mental cost-effectiveness ratios (ICERs) were calculated from
each model by dividing the incremental costs by the incremen-
tal QALYs. The decision whether the strategy is deemed cost-
effective then depends on how much society is willing to pay
for a QALY gained. In The Netherlands the informal societal
willingness to pay (WTP) threshold level is 80,000 € ($
106,000) [27]. If the ICER is lower than this level, we
conclude that the strategy is cost-effective compared with the
alternative. Additionally, a scenario analysis was performed in
which, for all patients, DSA was performed in case an aneu-
rysm was visible but coiling was deemed not feasible.
Sensitivity analysis
Uncertainty regarding the model input parameters was ex-
plored with a probabilistic sensitivity analysis using Monte
Carlo simulation [20, 28]. For this purpose we assigned dis-
tributions to all uncertain parameter. With Monte Carlo simu-
lation, 1,000 different samples were taken from these param-
eter distributions. For each sample, the hypothetical cohort
runs through the model based on these sampled probabilities,
and costs and effects are derived. This results in 1,000 esti-
mates of costs and effects for the hypothetical cohort,
representing the uncertainty in the cost-effectiveness estima-
tion [18]. All assigned distributions are listed in Table 1.
To illustrate the results of the simulation, cost-effectiveness
acceptability curves (CEACs) were calculated [29]. CEACs
show the probability that a strategy is cost-effective, given
different values of willingness to pay for a QALY.
Additionally, univariate sensitivity analyseswere performed for
test characteristics and costs of DSA, MRA and CTA, as well as
for costs of coiling and clipping, to determine association between
these model input parameters and cost-effectiveness outcome.
Results
Basic model
Comparing expected average 1-year health benefits, DSA was
the most effective diagnostic option, yielding 0.6039 QALYs
(95 % CI, 0.5761–0.6327), followed by CTA yielding 0.5983
QALYs (95 % CI, 0.5704–0.6278) and MRA yielding 0.5947
QALYs (95 % CI, 0.5674–0.6237). The total expected 1-year
health costs were lowest for DSA (39,808 €; 95 % CI, 37,182–
42,663), followed by CTA (40,748 €; 95 % CI, 37,937–43,831)
andMRA (41,814 €; 95%CI, 38,730–45,146). Initial diagnostic
costs were highest for DSA, while therapy and health state-
related costs were lowest for DSA, resulting in DSA being the
least costly diagnostic option. CTA as diagnostic test resulted in
128 out of 1,000 patients being referred for clipping although
coilingwould have been feasible.WithMRA, 187 patients out of
1,000 were treated surgically, although endovascular treatment
would have been feasible. DSAwas both more effective and less
costly and dominated CTA and MRA. CTAwas more effective
and less costly than MRA and thus dominated MRA. Table 2
shows costs and QALYs for the three diagnostic tests.
Scenario model
The strategy that included DSA for every patient for whom
coiling was not deemed feasible on the basis of CTA and
MRA, led to equal effectiveness for DSA, MRA and CTA
(0.6039 QALYs each). In this approach no patient was
Table 1 (continued)
pMRAtpT (sensitivity of MRA in determining whether coiling is feasible) 0.606 0.058 beta b
pMRAtnT (specificity of MRA in determining whether coiling is feasible) 0.814 0.050 beta b
pCTAtpT (sensitivity of CTA in determining whether coiling is feasible) 0.719 0.056 beta b
pCTAtnT (specificity of CTA in determining whether coiling is feasible) 0.754 0.057 beta b
pDSAtpD (sensitivity of DSA in diagnosing aneurysm) 1 fixed [19]
pDSAtnD (Specificity DSA in diagnosing aneurysm) 1 fixed [19]
pDSAtpT (sensitivity of DSA in determining whether coiling is feasible) 1 fixed [19]
pDSAtnT (specificity of DSA in determining whether coiling is feasible) 1 fixed [19]
a Range presented for triangular distributions
b Data based on study [19]
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treated surgically unless coiling was no option. In this sce-
nario, CTAwas estimated less costly, reaching a total average
1-year cost per patient of 39,767 €, and therefore cost-
effective compared with MRA and DSA, which reached
costs of 39,851 € and 39,808 € respectively. Table 3 shows
total expected 1-year costs and QALYs as well as incremen-
tal costs and QALYs for diagnostic tests in the scenario
analysis and basic model.
Sensitivity analysis
In univariate sensitivity analyses we explored whether chang-
ing individual parameters altered the conclusions of our base
case analysis. Assuming equal treatment cost for coiling and
clipping did not change the conclusions. Furthermore, results
remained stable for the assumption of higher costs of DSA up
to factor 2.8. Higher sensitivity and specificity for detection of
aneurysms and determination of feasibility of coiling for CTA
and MRA up to 96 % or a reduction of sensitivity and
specificity for DSA to 90 % also yielded stable results. In
the scenario analysis, the strategy where CTA is followed by
DSA remained the least costly strategy for a sensitivity of
determination of coiling within the range of 60–100 %. The
probabilistic sensitivity analysis showed that in the basic
model analysis, DSA had a 98–100 % probability of being
cost-effective. In the scenario analysis, CTA had the highest
probability of being cost-effective (91 %), followed by DSA
(9 %) and MRA (0 %). Because in the scenario analysis
effectiveness is equal for all strategies, CEACs are constant
over the different values of willingness to pay for a QALY.
Discussion
When a patient presents with a suspected ruptured intracra-
nial aneurysm, imaging is a challenge. Due to high risk of
case fatality in ruptured intracranial aneurysms, timely de-
tection of a causative aneurysm and determination of
appropriate treatment are mandatory. Based on imaging re-
sults, patients may be left untreated, or their aneurysms
clipped surgically, or they receive endovascular treatment.
In recent years, much research has been done to evaluate the
best treatment options and to optimise the approach to im-
aging modalities. In particular, the role and necessity of DSA
in this patient population has been widely discussed [31–34].
In our study we compared the diagnostic work-up by CTA,
MRA and DSA based on a cost-effectiveness approach. We
found that DSA is more cost-effective than CTA, which is in
turn superior to MRA. A combination strategy of CTA
followed by DSA if endovascular treatment is deemed not
feasible was found to be as effective as DSA alone at slightly
lower expected costs.
Our analysis is based on a 1-year horizon. This holds
potential conflict concerning the long-term validity of the
results. Probabilities of health outcome which we clustered
from the ISAT trial are relatively stable in the long run and do
not change our results [8]. Incomplete occlusion and refilling
of the aneurysm is a complication occurring mainly in
coiling which can cause rebleeding, resulting in a higher rate
of follow-up imaging costs and re-interventions in the
endovascular group. The rate of recanalisation is highest in
the first months and decreases significantly over time
[35–38]. Follow-up for detection of recanalisation after 6
months may not be necessary [36]. Wolstenholme et al.
[10] determined cost of coiling and clipping in the first year
for western countries. Calculation of total costs for both
treatment options included not only cost for material, inten-
sive care and standard unit days and medication but also cost
of follow-up imaging and re-intervention for the first year.
Taking the results from literature, we can assume that the
validity of our data will be stable for the following years.
Our basic model results show that DSA is the most cost-
effective imaging modality and is superior to both MRA and
CTA. Although initial test costs are about three times higher
than those of MRA and CTA, optimal detection of aneurysms
and determination of treatment in DSA yield lower overall 1-
Table 2 Related 1-year costs and QALYs for MRA, CTA and DSA per patient in the basic model
MRA CTA DSA
Costs (€) QALYs Costs (€) QALYs Costs (€) QALYs
MRA resp. CTA 252 0.5947 197 0.5983 0.6039
DSA 168a 214a 725
Total diagnostic 420 411 725
Treatment 26,734 26,120 25,553
Death 217 212 205
Disability costs 14,443 14,005 13,325
Total 41,814 0.5947 40,748 0.5983 39,808 0.6039
a Average costs per patient for DSA performed in case CTA/MRA showing no aneurysm
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year costs per patient and the highest QALYs. Themorbidity of
DSA, although low, was included as an input parameter in our
model [17, 24]. Nevertheless, we did not consider the potential
influence of test-related short-term disutility described by
Swan et al. [39]. Depending on the severity grade of clinical
presentation, the short-term discomfort undergoing DSA ex-
perienced by patients with SAH might be of varying impor-
tance and influence to our model might be less compared with
in elective imaging.
We assumed DSA to be the standard of reference with
sensitivity and specificity for detection and determination of
treatment of 100 %. It is debatable whether sensitivity of
DSA to cerebral aneurysms is 100 % in an acute setting [40].
When coiling was performed, costs for diagnostic DSAwere
accounted for separately. Costs of imaging were estimated at
725 €, following the Dutch costing guideline [21]. Actual
costs of DSA might be higher than in our model and likely
differ in other countries. We therefore performed sensitivity
analysis showing stable results for assumption of 90 % sen-
sitivity and specificity in aneurysm detection and coilability,
as well as costs up to 2,025 € for DSA. Given this range of
diagnostic performance and costs, other researchers or
decision-makers can assess transferability of the results to
their specific situation and jurisdiction [41]. Differences
between United States cost estimates and European cost
estimates, in particular, may not change conclusions, as costs
are proportionally higher in the United States [42].
The test characteristics for CTA andMRA are based on our
study performed with 75 patients. In literature, meta-analyses
of test characteristics of CTA as well as other studies show
higher sensitivity and specificity for CTA and MRA in the
detection of aneurysms and determination of treatment com-
pared with our study [43–45]. Since our basic model results
are stable in sensitivity analysis with assumption of 96 %
sensitivity and specificity for aneurysm detection as well as
determination of treatment for CTA andMRA, we can assume
that our conclusion is valid in a broad range of diagnostic
performance. In the scenario model sensitivity analysis, in-
creasing sensitivity and specificity for CTA and MRA shows
even increasing preference of our imaging strategy starting
with non-invasive imaging compared with only DSA.
Comparing the two non-invasive imaging modalities,
CTA dominated MRA in the basic model and thus was
superior. This was mainly due to lower sensitivity in deter-
mination of feasibility of coiling in MRA. Beside its inferi-
ority in cost-effectiveness, MRA has limitations as first line
imaging in acute settings, as it might be unavailable during
night hours and not applicable in severe clinical presentation.
Our scenario model with initial CTA followed by DSA in
case an aneurysm is detected but deemed not suitable for
coiling was found to be the most cost-effective imaging strat-
egy overall. The slightly lower costs compared with only DSA
result from the group of patients where on CTA an aneurysm
is detected which is deemed feasible for coiling. In this group
endovascular treatment will be initiated without previous di-
agnostic DSA. Nevertheless comparing these two approaches,
the average reduction in costs per patient is 40 €, which is
marginal in comparison to the overall 1-year costs. In case of
suspected SAH, standard diagnostic imaging is non-contrast
enhanced CT (NECT), followed by examination of CSF,
obtained by lumbar puncture, if NECT is negative [46]. In
case a SAH is detected on NECT, performing an additional
CTA study can be assumed to be less expensive than the total
CTA cost that we used as an input parameter in our model. In
fact only additional contrast application would need to be
accounted for. Considering this, we might assume that the
Table 3 Total one-year outcome and incremental cost-effectiveness ratio (ICER) for basic and scenario model
Costs (€) (95 % CI) QALYs (95 % CI)
Basic model
DSA 39,808 (37,182 ; 42,663) 0.6039 (0.5761 ; 0.6327)
CTA 40,748 (37,937 ; 43,831) 0.5983 (0.5704 ; 0.6278)
MRA 41,814 (38,730 ; 45,146) 0.5947 (0.5674 ; 0.6237)
Scenario model
DSA 39,808 (36,982 ; 42,414) 0.6039 (0.5771 ; 0.6333)
CTA 39,767 (36,903 ; 42,402) 0.6039 (0.5771 ; 0.6333)
MRA 39,851 (37,003 ; 42,486) 0.6039 (0.5771 ; 0.6333)
Incremental costs (€) (95 % CI) Incremental QALYs (95 % CI) ICER (€ per QALY) Comparator
Basic model
DSA
CTA 940 (10 ; 2,122) −0.006 (−0.003 ; −0.009) Dominated DSA
MRA 2,007 (604 ; 3,767) −0.009 (−0.005 ; −0.015) Dominated DSA
Scenario model
DSA
CTA −40 (−103 ; 20) 0.000 (0.000 ; 0.000) Dominant DSA
MRA 84 (−15 ; 98) 0.000 (0.000 ; 0.000) Dominated CTA
CI Confidence Interval (calculated based on the probabilistic sensitivity analysis)
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actual cost advantage of the scenario strategy will likely be
higher.
There are heated discussions about whether or not to always
perform DSA in patients with suspected ruptured intracranial
aneurysms [47–56]. Our study contributes to this discussionwith
two important findings. First, DSA is both more effective, yield-
ing higher QALYs, and less costly in overall costs than CTA and
MRA. DSA is therefore superior to the non-invasive imaging
modalities and should play a key role in diagnostic work-up of
non-traumatic SAH. Second, we analysed a scenario that com-
bines invasive and non-invasive diagnostic tests. We found the
less costly and therefore most efficient diagnostic approach
overall to be a strategy, starting with CTA as the first examina-
tion, followed by DSA if coiling is not deemed feasible. This
means that every patient undergoes additional DSA unless an
aneurysm has been detected and deemed suitable for
endovascular coiling. This strategy yields the same amount of
QALYs compared with DSA alone in all patients, but results in
lower average costs per patient. In comparison to diagnostic
DSA, CTA is easily available during night hours and can directly
be performed on hospital admission. This further emphasises
CTA as a first-line imaging strategy, as it may fasten clinical
treatment decisions and therefore help avoid rebleedings.
Besides representing the most cost-effective approach over-
all, we believe that the strategy of combining CTA and DSA
also represents the most practical approach in routine clinical
practice. For patients with suspected SAH, we therefore rec-
ommend performing a non-contrast enhanced CTscan first. If a
SAH is demonstrated, CTA is directly performed. When CTA
shows no aneurysm or shows an aneurysm which is not suit-
able for coiling, an additional DSA study should be performed.
Conclusions
For diagnostic work-up of suspected ruptured intracranial
aneurysms, a combined strategy of CTA followed by DSA if
CTA is negative or endovascular treatment deems not feasible
is found to be as the most cost-effective approach overall.
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